NL-OMON30850
Completed
Not Applicable
A Blinded, Placebo-Controlled, Randomized, Single Ascending Dose Study in Healthy Male Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-37822681 - N/A
Johnson & Johnson Pharmaceutical0 sites24 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- psychosis
- Sponsor
- Johnson & Johnson Pharmaceutical
- Enrollment
- 24
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •healthy male subjects between 18 \- 55 years of age
- •BMI between 18 and 30 kg/m²
Exclusion Criteria
- •History of, or currently active, significant illness or medical disorder
- •History of epilepsy or fits or unexplained black\-outs
- •Significant history of or current neurological disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Adult VolunteersdemyelinationMS10012303NL-OMON32724Biogen64
Active, not recruiting
Phase 1
Avexxin (AVX001) 3% Ointment (NG) in Atopic Dermatitis – safety and efficacy studyEUCTR2016-003013-96-DKAvexxin AS
Completed
Phase 2
Clinical study to evaluate the safety and efficacy of ATRICOV 452 for the treatment of COVID-19 along with the standard of care.CTRI/2021/01/030795Atrimed Pharmaceutical Pvt Ltd95
Completed
Phase 2
Covid Investigator Initiate Study on ProbenecidCTRI/2022/07/043726Dr Neelam Pandey75
Completed
Phase 1
A study to learn how safe elinzanetant is, how it affects the body, and how it moves into, through and out of the body after single and multiple doses in Japanese healthy female adultsJPRN-jRCT2071210049Myoishi Masashi62